HLS Therapeutics Inc Cash Flow Conversion Efficiency
HLS Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, HLS Therapeutics Inc (HLS) has a cash flow conversion efficiency ratio of 0.105x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$6.44 Million ≈ $4.66 Million USD) by net assets (CA$61.56 Million ≈ $44.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of HLS Therapeutics Inc (1996–2025)
Cash flow conversion efficiency of HLS Therapeutics Inc from 1996 to 2025. This chart illustrates how HLS Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HLS Therapeutics Inc stock quote for real-time trading data and today's change.
HLS Therapeutics Inc Cash Flow Conversion Ratio Explained
HLS Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
HLS Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HLS Therapeutics Inc ranked by their cash flow conversion efficiency. Also see HLS Therapeutics Inc (HLS) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Calida Holding AG
SW:CALN
|
-0.056x |
|
SOTKAMO SILVER AB NAM.
F:VSO
|
0.214x |
|
Coda Octopus Group Inc
NASDAQ:CODA
|
0.035x |
|
Terra Metals Ltd
AU:TM1
|
-0.001x |
|
Nahar Spinning Mills Limited
NSE:NAHARSPING
|
0.219x |
|
Bioneer Corporation
KQ:064550
|
0.004x |
|
Optical Cable Corporation
NASDAQ:OCC
|
0.062x |
|
Grupo Ortiz Properties Socimi
MC:YGOP
|
0.009x |
Annual Cash Flow Conversion Efficiency for HLS Therapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of HLS Therapeutics Inc from 1996 to 2025. Review free cash flow generation of HLS Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$61.56 Million ≈ $44.53 Million |
CA$16.02 Million ≈ $11.59 Million |
0.260x | +131.95% |
| 2024-12-31 | CA$71.34 Million ≈ $51.61 Million |
CA$8.00 Million ≈ $5.79 Million |
0.112x | -30.59% |
| 2023-12-31 | CA$97.70 Million ≈ $70.67 Million |
CA$15.79 Million ≈ $11.42 Million |
0.162x | +19.54% |
| 2022-12-31 | CA$125.32 Million ≈ $90.65 Million |
CA$16.94 Million ≈ $12.26 Million |
0.135x | +32.27% |
| 2021-12-31 | CA$160.74 Million ≈ $116.27 Million |
CA$16.43 Million ≈ $11.88 Million |
0.102x | +85.14% |
| 2020-12-31 | CA$169.25 Million ≈ $122.43 Million |
CA$9.34 Million ≈ $6.76 Million |
0.055x | -62.75% |
| 2019-12-31 | CA$178.20 Million ≈ $128.91 Million |
CA$26.41 Million ≈ $19.10 Million |
0.148x | -28.28% |
| 2018-12-31 | CA$158.49 Million ≈ $114.65 Million |
CA$32.75 Million ≈ $23.69 Million |
0.207x | +37.20% |
| 2017-12-31 | CA$180.38 Million ≈ $130.49 Million |
CA$27.17 Million ≈ $19.65 Million |
0.151x | +3562.31% |
| 2016-12-31 | CA$24.97 Million ≈ $18.06 Million |
CA$-108.62K ≈ $-78.58K |
-0.004x | +96.16% |
| 2015-12-31 | CA$26.03 Million ≈ $18.83 Million |
CA$-2.94 Million ≈ $-2.13 Million |
-0.113x | -129.05% |
| 2014-12-31 | CA$46.75 Million ≈ $33.82 Million |
CA$18.21 Million ≈ $13.17 Million |
0.389x | -12.46% |
| 2013-12-31 | CA$40.53 Million ≈ $29.32 Million |
CA$18.03 Million ≈ $13.04 Million |
0.445x | -14.10% |
| 2012-12-31 | CA$40.99 Million ≈ $29.65 Million |
CA$21.23 Million ≈ $15.36 Million |
0.518x | -5.88% |
| 2011-12-31 | CA$32.56 Million ≈ $23.55 Million |
CA$17.92 Million ≈ $12.96 Million |
0.550x | -27.03% |
| 2010-12-31 | CA$33.23 Million ≈ $24.04 Million |
CA$25.06 Million ≈ $18.13 Million |
0.754x | +408.59% |
| 2009-12-31 | CA$35.90 Million ≈ $25.97 Million |
CA$5.32 Million ≈ $3.85 Million |
0.148x | -24.36% |
| 2008-12-31 | CA$28.33 Million ≈ $20.50 Million |
CA$5.55 Million ≈ $4.02 Million |
0.196x | -55.32% |
| 2007-12-31 | CA$50.09 Million ≈ $36.24 Million |
CA$21.98 Million ≈ $15.90 Million |
0.439x | +1816.11% |
| 2006-12-31 | CA$30.72 Million ≈ $22.23 Million |
CA$703.50K ≈ $508.90K |
0.023x | -94.50% |
| 2005-12-31 | CA$30.02 Million ≈ $21.72 Million |
CA$12.50 Million ≈ $9.04 Million |
0.416x | +208.31% |
| 2004-12-31 | CA$18.42 Million ≈ $13.33 Million |
CA$2.49 Million ≈ $1.80 Million |
0.135x | -26.74% |
| 2003-12-31 | CA$26.67 Million ≈ $19.30 Million |
CA$4.92 Million ≈ $3.56 Million |
0.184x | -35.68% |
| 2002-12-31 | CA$24.47 Million ≈ $17.70 Million |
CA$7.01 Million ≈ $5.07 Million |
0.287x | +135.36% |
| 2001-12-31 | CA$24.45 Million ≈ $17.69 Million |
CA$2.98 Million ≈ $2.15 Million |
0.122x | -76.93% |
| 2000-12-31 | CA$12.48 Million ≈ $9.03 Million |
CA$6.59 Million ≈ $4.77 Million |
0.528x | +64.79% |
| 1999-12-31 | CA$14.22 Million ≈ $10.29 Million |
CA$4.56 Million ≈ $3.30 Million |
0.320x | +5033.98% |
| 1998-12-31 | CA$10.01 Million ≈ $7.24 Million |
CA$-64.99K ≈ $-47.01K |
-0.006x | -101.99% |
| 1997-12-31 | CA$16.91 Million ≈ $12.23 Million |
CA$5.52 Million ≈ $3.99 Million |
0.326x | -70.75% |
| 1996-12-31 | CA$8.31 Million ≈ $6.01 Million |
CA$9.27 Million ≈ $6.71 Million |
1.116x | -- |
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances … Read more